Kim S - Search Results

1

Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.

Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Chamberlain MC, et al. Among authors: kim s, kim jc. Arch Neurol. 1993 Mar;50(3):261-4. doi: 10.1001/archneur.1993.00540030027009. Arch Neurol. 1993. PMID: 8442704 Clinical Trial.

2

Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.

Chamberlain MC, Kormanik P, Howell SB, Kim S. Chamberlain MC, et al. Among authors: kim s. Arch Neurol. 1995 Sep;52(9):912-7. doi: 10.1001/archneur.1995.00540330094020. Arch Neurol. 1995. PMID: 7661730

3

Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, Chamberlain MC. Kim S, et al. Among authors: kim jc. J Clin Oncol. 1993 Nov;11(11):2186-93. doi: 10.1200/JCO.1993.11.11.2186. J Clin Oncol. 1993. PMID: 8229133

4

An extended-release formulation of methotrexate for subcutaneous administration.

Bonetti A, Chatelut E, Kim S. Bonetti A, et al. Among authors: kim s. Cancer Chemother Pharmacol. 1994;33(4):303-6. doi: 10.1007/BF00685904. Cancer Chemother Pharmacol. 1994. PMID: 8281623

5

A slow-release methotrexate formulation for intrathecal chemotherapy.

Chatelut E, Kim T, Kim S. Chatelut E, et al. Among authors: kim t, kim s. Cancer Chemother Pharmacol. 1993;32(3):179-82. doi: 10.1007/BF00685832. Cancer Chemother Pharmacol. 1993. PMID: 8500221

6

Quantitative cerebrospinal fluid cytology in patients receiving intracavitary chemotherapy.

Russack V, Kim S, Chamberlain MC. Russack V, et al. Among authors: kim s. Ann Neurol. 1993 Jul;34(1):108-12. doi: 10.1002/ana.410340118. Ann Neurol. 1993. PMID: 8517670

7

Sustained-release methotrexate for intracavitary chemotherapy.

Chatelut E, Suh P, Kim S. Chatelut E, et al. Among authors: kim s. J Pharm Sci. 1994 Mar;83(3):429-32. doi: 10.1002/jps.2600830333. J Pharm Sci. 1994. PMID: 8207696

8

Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.

Isonishi S, Kirmani S, Kim S, Plaxe SC, Braly PS, McClay EF, Howell SB. Isonishi S, et al. Among authors: kim s. J Natl Cancer Inst. 1991 May 1;83(9):621-6. doi: 10.1093/jnci/83.9.621. J Natl Cancer Inst. 1991. PMID: 2023280 Clinical Trial.

9

A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.

Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. Kirmani S, et al. Among authors: kim s. J Clin Oncol. 1991 Apr;9(4):649-57. doi: 10.1200/JCO.1991.9.4.649. J Clin Oncol. 1991. PMID: 2066761 Clinical Trial.

10

Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes.

Kim S, Scheerer S, Geyer MA, Howell SB. Kim S, et al. J Infect Dis. 1990 Sep;162(3):750-2. doi: 10.1093/infdis/162.3.750. J Infect Dis. 1990. PMID: 2167343

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124,511 results

Search Page

Filters